BRISTOL-MYERS SQUIBB CO

FDA expands CAMZYOS® to treat symptomatic obstructive hypertrophic cardiomyopathy in patients 30 kg+, offering a non‑surgical, evidence‑based option for adults and children.

Discover how Bristol‑Myers Squibb’s new liquid apixaban could reshape the anticoagulant market, boost patient compliance, and impact investor strategy.

Executive insider buys at BMY signal confidence in its oncology pipeline and growing value‑based contracts, highlighting strategic moves for long‑term growth.

Investor insights on Bristol‑Myers Squibb: how a focus on R&D, value‑based contracts and strategic acquisitions drives long‑term growth amid short‑term revenue dips.

Investor insights on Bristol‑Myers Squibb’s oncology future: pricing pressure, patent cliffs, and M&A strategies reveal why the market remains cautious.

Discover how Bristol‑Myers Squibb’s latest revenue dip, R&D focus, and cost‑cutting strategy shape its future growth and investor outlook.

BMS pauses autoimmune CAR‑T trials amid industry safety review, balancing innovation with risk, and setting the stage for stronger regulatory and payer confidence.

How Bristol‑Myers Squibb’s pipeline, strategic partnerships and regulatory focus shape its growth—insights on oncology, immune‑mediated diseases and smarter acquisitions.

Explore how a potential merger between AstraZeneca and Bristol‑Myers Squibb could reshape oncology, R&D and global market reach, boosting investor value and industry dynamics.

Investors eye Bristol‑Myers Squibb as a low‑beta, steady‑growth pharma stock—balanced legacy revenue, hefty R&D, and a growing oncology pipeline amid tech‑driven market swings.